)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Hologic
Hologic (HOLX) investor relations material
Hologic has been acquired by TPG Inc
Hologic Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary29 Jan, 2026
Executive summary
Entered into a definitive agreement to be acquired by Blackstone and TPG for up to $79.00 per share, including a contingent value right tied to Breast Health revenue metrics; transaction expected to close in H1 2026, pending approvals.
Revenue reached $1,047.8 million, up 2.5% year-over-year, with organic revenue excluding COVID-19 and certain businesses up 2.9%.
GAAP diluted EPS was $0.79, down 9.2%, while non-GAAP diluted EPS rose 1.0% to $1.04.
Completed the acquisition of Gynesonics for $340.7 million, expanding the GYN Surgical segment.
Resolved BioZorb litigation with no financial liability due to insurance coverage.
Financial highlights
Revenue for the quarter ended December 27, 2025 was $1,047.8 million, up 2.5% year-over-year.
Net income was $179.1 million, down from $201.0 million in the prior year quarter.
Diluted EPS was $0.79, compared to $0.87 in the prior year quarter.
Operating cash flow was $229.9 million, up from $189.3 million year-over-year.
Cash and cash equivalents at quarter end were $2,168.0 million.
Outlook and guidance
Management expects the merger to close in the first half of 2026, subject to customary conditions.
No annual or quarterly financial guidance for fiscal 2026 is being provided due to the pending acquisition.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hologic
- Stockholders to vote on Blackstone/TPG acquisition as Q1 revenue rises 2.5%.HOLX
Proxy Filing - Merger, litigation, and product recall updates shape shareholder decisions and future outlook.HOLXProxy Filing
- Shareholders to receive $76 per share plus CVR in Blackstone/TPG acquisition, with key risks disclosed.HOLXProxy Filing
- Strong Q4, 2025 growth guided at 4%, with innovation and M&A fueling future expansion.HOLX7th Annual Evercore ISI HealthCONx Conference
- Q4 revenue up 4.5% with strong segment growth; FY2025 targets 4% organic growth and margin gains.HOLXQ4 2024
- International growth, recurring revenue, and innovation drive strong performance and future outlook.HOLXMorgan Stanley 22nd Annual Global Healthcare Conference
- Q3 revenue and EPS exceeded guidance, led by strong core segment growth and margin gains.HOLXQ3 2024
- Strong growth, innovation, and global expansion drive robust financial and operational performance.HOLXThe 44th Annual William Blair Growth Stock Conference
- Q2 revenue and non-GAAP EPS met guidance, but large impairments drove negative GAAP EPS.HOLXQ2 2025
Hologic
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. The company offers technologies for mammography, 3D breast tomosynthesis (MammoSite(TM)), and FDA-cleared digital breast tomosynthesis (3D mammography); gynecologic imaging systems; and instruments for gynecology procedures; as well as software for diagnostic oncology centers and breast imaging. It also provides surgical services to support pre-, intra-, and postoperative care by surgeons or oncologists; preoperative planning tools for tumor management; and pathology review tools. In addition, the company offers facial aesthetics products comprising of injection devices designed to enhance aesthetics in patients undergoing anti-aging or cosmetic treatments such as neuromodulators that are used to smooth wrinkles and fine lines around the eyes.